These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 31466958)

  • 1. Eluxadoline-induced pancreatitis occurring in an adult man without a prior cholecystectomy.
    Shahid Z; Packard E; Groff A; Jain R
    BMJ Case Rep; 2019 Aug; 12(8):. PubMed ID: 31466958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eluxadoline-Associated Pancreatitis in a Post-Cholecystectomy Patient: A Case Report.
    Chhaparia A; Hammami MB; Vareedayah A; Schroeder K
    Del Med J; 2017 Mar; 89(3):90-92. PubMed ID: 29894043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea.
    Cash BD; Lacy BE; Schoenfeld PS; Dove LS; Covington PS
    Am J Gastroenterol; 2017 Feb; 112(2):365-374. PubMed ID: 27922029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of Pancreatitis Following Treatment of Irritable Bowel Syndrome With Eluxadoline.
    Gawron AJ; Bielefeldt K
    Clin Gastroenterol Hepatol; 2018 Mar; 16(3):378-384.e2. PubMed ID: 28804032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In brief: Pancreatitis with eluxadoline (Viberzi) in patients without a gallbladder.
    Med Lett Drugs Ther; 2017 Apr; 59(1519):70. PubMed ID: 28419076
    [No Abstract]   [Full Text] [Related]  

  • 6. Update on Eluxadoline for the Treatment of Irritable Bowel Syndrome with Diarrhea: Patient Selection and Perspectives.
    Liu R; Staller K
    Drug Des Devel Ther; 2020; 14():1391-1400. PubMed ID: 32308371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eluxadoline for Irritable Bowel Syndrome with Diarrhea.
    Lembo AJ; Lacy BE; Zuckerman MJ; Schey R; Dove LS; Andrae DA; Davenport JM; McIntyre G; Lopez R; Turner L; Covington PS
    N Engl J Med; 2016 Jan; 374(3):242-53. PubMed ID: 26789872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eluxadoline: A Review in Diarrhoea-Predominant Irritable Bowel Syndrome.
    Keating GM
    Drugs; 2017 Jun; 77(9):1009-1016. PubMed ID: 28493170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postmarketing cases of eluxadoline-associated pancreatitis in patients with or without a gallbladder.
    Harinstein L; Wu E; Brinker A
    Aliment Pharmacol Ther; 2018 Mar; 47(6):809-815. PubMed ID: 29349789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eluxadoline Demonstrates a Lack of Abuse Potential in Phase 2 and 3 Studies of Patients With Irritable Bowel Syndrome With Diarrhea.
    Fant RV; Henningfield JE; Cash BD; Dove LS; Covington PS
    Clin Gastroenterol Hepatol; 2017 Jul; 15(7):1021-1029.e6. PubMed ID: 28167156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eluxadoline Efficacy in IBS-D Patients Who Report Prior Loperamide Use.
    Lacy BE; Chey WD; Cash BD; Lembo AJ; Dove LS; Covington PS
    Am J Gastroenterol; 2017 Jun; 112(6):924-932. PubMed ID: 28417992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eluxadoline for the treatment of diarrhoea-predominant irritable bowel syndrome.
    Scarpellini E; Laterza L; Ianiro G; Tack J; Abenavoli L; Gasbarrini A
    Expert Opin Pharmacother; 2016 Jul; 17(10):1395-402. PubMed ID: 27267380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rifaximin and eluxadoline - newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron?
    Cash BD; Lacy BE; Rao T; Earnest DL
    Expert Opin Pharmacother; 2016; 17(3):311-22. PubMed ID: 26559529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eluxadoline-induced Recurrent Pancreatitis in a Young Female without a Gallbladder: A Case Report and Literature Review.
    Khetpal N; Yadav L; Khalid S; Kumar R
    Cureus; 2018 Dec; 10(12):e3747. PubMed ID: 30820368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome.
    Özdener AE; Rivkin A
    Drug Des Devel Ther; 2017; 11():2827-2840. PubMed ID: 29033544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.
    Dove LS; Lembo A; Randall CW; Fogel R; Andrae D; Davenport JM; McIntyre G; Almenoff JS; Covington PS
    Gastroenterology; 2013 Aug; 145(2):329-38.e1. PubMed ID: 23583433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging treatments in neurogastroenterology: eluxadoline - a new therapeutic option for diarrhea-predominant IBS.
    Lacy BE
    Neurogastroenterol Motil; 2016 Jan; 28(1):26-35. PubMed ID: 26690872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New therapeutic options for IBS: the role of the first in class mixed µ- opioid receptor agonist and δ-opioid receptor antagonist (mudelta) eluxadoline.
    Corsetti M; Whorwell P
    Expert Rev Gastroenterol Hepatol; 2017 Apr; 11(4):285-292. PubMed ID: 28276811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eluxadoline in irritable bowel syndrome with diarrhea: rationale, evidence and place in therapy.
    Barshop K; Staller K
    Ther Adv Chronic Dis; 2017 Nov; 8(11):153-160. PubMed ID: 29090081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ▼ Eluxadoline for IBS-D.
    Drug Ther Bull; 2017 Aug; 55(8):90-93. PubMed ID: 28808081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.